RATIONALE: D-Cycloserine (DCS), a partial glutamate N-methyl-D-aspartate (NMDA) receptor agonist, enhances extinction of conditioned fear responding; preliminary data suggest that it may facilitate extinction of drug cue reactivity. OBJECTIVE: This study investigates DCS effects on cocaine cue craving and drug use in cocaine-dependent subjects. METHODS:Thirty-two subjects were randomly assigned to receive (1) DCS only, (2) DCS before sessions 1 and 3, placebo (PBO) before session 2, or (3) PBO only 15-min before each of 3 1-h cocaine cue exposure sessions conducted 1 day apart. Craving ratings were obtained before, during, and after sessions. Drug use and cue-induced craving were assessed 1 week after the last cue session. RESULTS: Repeated presentation of cocaine cues resulted in decreased craving both within and between sessions. DCS did not facilitate extinction learning and may have enhanced craving. The group that received three doses of DCS had significantly higher craving than the PBO group at the baseline ratings taken before sessions 2 and 3, as well as significantly higher cue-induced craving at follow-up. The group that received two doses of DCS did not differ from the PBO group. There were no group differences in postextinction cocaine use. CONCLUSIONS: The reduction of cocaine cue reactivity in the PBO group suggests that the study procedures were sufficient to produce extinction. Under these conditions, DCS did not facilitate extinction and may have enhanced craving. Further studies of glutamatergic agents and extinction in cocaine dependence should include consideration of procedural variables that could have a major impact on study outcomes.
RCT Entities:
RATIONALE: D-Cycloserine (DCS), a partial glutamate N-methyl-D-aspartate (NMDA) receptor agonist, enhances extinction of conditioned fear responding; preliminary data suggest that it may facilitate extinction of drug cue reactivity. OBJECTIVE: This study investigates DCS effects on cocaine cue craving and drug use in cocaine-dependent subjects. METHODS: Thirty-two subjects were randomly assigned to receive (1) DCS only, (2) DCS before sessions 1 and 3, placebo (PBO) before session 2, or (3) PBO only 15-min before each of 3 1-h cocaine cue exposure sessions conducted 1 day apart. Craving ratings were obtained before, during, and after sessions. Drug use and cue-induced craving were assessed 1 week after the last cue session. RESULTS: Repeated presentation of cocaine cues resulted in decreased craving both within and between sessions. DCS did not facilitate extinction learning and may have enhanced craving. The group that received three doses of DCS had significantly higher craving than the PBO group at the baseline ratings taken before sessions 2 and 3, as well as significantly higher cue-induced craving at follow-up. The group that received two doses of DCS did not differ from the PBO group. There were no group differences in postextinction cocaine use. CONCLUSIONS: The reduction of cocaine cue reactivity in the PBO group suggests that the study procedures were sufficient to produce extinction. Under these conditions, DCS did not facilitate extinction and may have enhanced craving. Further studies of glutamatergic agents and extinction in cocaine dependence should include consideration of procedural variables that could have a major impact on study outcomes.
Authors: David A Baker; Krista McFarland; Russell W Lake; Hui Shen; Xing-Chun Tang; Shigenobu Toda; Peter W Kalivas Journal: Nat Neurosci Date: 2003-07 Impact factor: 24.884
Authors: Bríd A Nic Dhonnchadha; Jonathan J Szalay; Cindy Achat-Mendes; Donna M Platt; Michael W Otto; Roger D Spealman; Kathleen M Kantak Journal: Neuropsychopharmacology Date: 2010-01 Impact factor: 7.853
Authors: Michael W Otto; M Alexandra Kredlow; Jasper A J Smits; Stefan G Hofmann; David F Tolin; Rianne A de Kleine; Agnes van Minnen; A Eden Evins; Mark H Pollack Journal: Biol Psychiatry Date: 2015-09-25 Impact factor: 13.382
Authors: Matthew W Johnson; Natalie R Bruner; Patrick S Johnson; Kenneth Silverman; Meredith S Berry Journal: Exp Clin Psychopharmacol Date: 2019-08-01 Impact factor: 3.157
Authors: Jamie M Gauthier; Amy Lin; Bríd Á Nic Dhonnchadha; Roger D Spealman; Heng-Ye Man; Kathleen M Kantak Journal: Addict Biol Date: 2015-09-18 Impact factor: 4.280
Authors: James J Prisciandaro; Hugh Myrick; Scott Henderson; Aimee L McRae-Clark; Elizabeth J Santa Ana; Michael E Saladin; Kathleen T Brady Journal: Drug Alcohol Depend Date: 2013-03-14 Impact factor: 4.492
Authors: Matthew T Rich; Thomas B Abbott; Lisa Chung; Erol E Gulcicek; Kathryn L Stone; Christopher M Colangelo; TuKiet T Lam; Angus C Nairn; Jane R Taylor; Mary M Torregrossa Journal: J Neurosci Date: 2016-07-20 Impact factor: 6.167
Authors: Kathleen M Kantak; Jamie M Gauthier; Elon Mathieson; Eudokia Knyazhanskaya; Pedro Rodriguez-Echemendia; Heng-Ye Man Journal: Behav Brain Res Date: 2020-08-02 Impact factor: 3.332